(Q39675253)

13 September 2017

1 reference

title

Symposium on antimicrobial agents. The quinolones (English)

1 reference

13 September 2017

0 references

R C Walker

1

1 reference

13 September 2017

A J Wright

series ordinal

2

1 reference

13 September 2017

language of work or name

English

0 references

publication date

1 November 1987

1 reference

13 September 2017

1 reference

13 September 2017

volume

62

1 reference

13 September 2017

issue

11

1 reference

13 September 2017

page(s)

1007-1012

1 reference

The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

New antibiotics: areas of appropriate use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Lack of emergence of resistant fecal flora during successful prophylaxis of traveler's diarrhea with norfloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Ciprofloxacin in the treatment of acute bacterial diarrhea: a double blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Failure of norfloxacin to eradicate Chlamydia trachomatis in nongonococcal urethritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

In vitro activities of norfloxacin and ciprofloxacin against Mycobacterium tuberculosis, M. avium complex, M. chelonei, M. fortuitum, and M. kansasii

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Treatment of Penicillin-ResistantNeisseria gonorrhoeaewith Oral Norfloxacin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Norfloxacin in the therapy of uncomplicated gonorrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Pharmacokinetics and pharmacodynamics of ciprofloxacin in cystic fibrosis patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

Evaluation of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965073-3

10.1016/S0025-6196(12)65073-3

7 January 2021

Identifiers

DOI

1 reference

13 September 2017

1 reference